公开(公告)号：US20230339882A1

公开(公告)日：2023-10-26

申请号：US18016144

申请日：2021-07-22

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Hao WU ,  Wenmao WU ,  Ling LI ,  Zhan ZHANG ,  Feng WANG ,  Ding YUAN ,  Yunfei WU ,  Qiang CHEN ,  Han HAN ,  Jing GUO ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D471/10 ,  C07D513/10 ,  C07D498/10

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10 ,  C07D513/10

Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.

公开(公告)号：US20230192705A1

公开(公告)日：2023-06-22

申请号：US18009277

申请日：2021-06-10

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Bang FU ,  Zhongxin SUN ,  Xiaofeng XU ,  Wei REN ,  Yinlong LI ,  Ling LI ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

Abstract: Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

公开(公告)号：US20160137658A1

公开(公告)日：2016-05-19

申请号：US14896707

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Shaojing Hu ,  Wei LONG ,  Fei WANG ,  Yinxiang WANG ,  Lieming DING

IPC: C07D491/056 ,  C07C57/145 ,  A61K31/519

CPC classification number: C07D491/056 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07B2200/13 ,  C07C57/145 ,  A61K2300/00

Abstract: Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them.

Abstract translation: 提供马来酸伊西替尼（式I化合物）及其多晶型形式，以及制备和使用它们的方法。

公开(公告)号：US20250042853A1

公开(公告)日：2025-02-06

申请号：US18706666

申请日：2022-11-03

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Rongwen YANG ,  Yun SUN ,  Jian ZHANG ,  Xuegang YI ,  Teng MA ,  Yu WANG ,  Pingping WANG ,  Lieming DING ,  Hong LAN ,  Jiabing WANG

IPC: C07D209/22 ,  A61K31/403 ,  A61K31/407 ,  A61K31/437 ,  A61K31/4709 ,  C07D209/30 ,  C07D209/52 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/052

Abstract: The present invention relates to a compound as shown in formula (I). The present invention also provides a composition and preparation containing the compound, and a method for using and preparing the compound.

公开(公告)号：US20240352053A1

公开(公告)日：2024-10-24

申请号：US18683571

申请日：2022-08-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Liang CHEN ,  Changyong QIU ,  Xiangyong LIU ,  Jian TANG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/6558 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04

CPC classification number: C07F9/65583 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04 ,  C07B2200/13

Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.

公开(公告)号：US20220402948A1

公开(公告)日：2022-12-22

申请号：US17763633

申请日：2020-09-25

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Haitong SHENG ,  Mengqiang LIU ,  Qichao SHEN ,  Guolong DU ,  Xiaodong SONG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/53

Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220119411A1

公开(公告)日：2022-04-21

申请号：US17259187

申请日：2019-07-12

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yao ZHANG ,  Yiqian WANG ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D513/04 ,  C07D471/04 ,  C07D498/04 ,  C07D519/00 ,  C07D487/04 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220098183A1

公开(公告)日：2022-03-31

申请号：US17427112

申请日：2020-01-20

Applicant: Betta Pharmaceuticals Co.,Ltd

Inventor： Yiqian WANG ,  Yao ZHANG ,  Bang FU ,  Jiabing WANG ,  Lieming DING

IPC: C07D413/14 ,  C07D487/04 ,  C07D471/10 ,  C07D495/10 ,  C07D487/08 ,  C07D451/02 ,  C07D491/107 ,  C07D498/04

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20210300909A1

公开(公告)日：2021-09-30

申请号：US17261013

申请日：2019-07-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Yiqian WANG ,  Yao ZHANG ,  Bang FU ,  Jiabing WANG ,  Lieming DING

IPC: C07D413/06 ,  C07D263/57 ,  C07D401/04 ,  C07D401/06 ,  C07D413/14 ,  C07D417/06 ,  C07D277/66

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20240327518A1

公开(公告)日：2024-10-03

申请号：US18294516

申请日：2022-08-05

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Wenxin XU ,  Xuefei FANG ,  Deyu XU ,  Lieming DING

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68

CPC classification number: C07K16/2818 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569

Abstract: Provided are an anti-PD-L1 nanobody and use thereof. The anti-PD-L1 nanobody comprises a CDR1, a CDR2, and a CDR3, wherein the CDR1 comprises a sequence selected from SEQ ID NOs: 1, 5, and 9; the CDR2 comprises a sequence selected from SEQ ID NOs: 2, 6, and 10; and the CDR3 comprises a sequence selected from SEQ ID NOs: 3, 7, 11, and 14. The antibody can block the PD-1/PD-L1 and CD-80/PD-L1 signaling pathways, inhibit the growth of tumor cells, and exhibit a therapeutic effect against tumors.